2023年1月4日,

除了时间与第四基金专注于公司追求生命科学和医疗技术的转型影响下载1月04,2023年塔利班)是纽约东部标准时间(业务线),洋地黄Misti Ushio公司今天宣布,博士已经加入了集团管理合伙人。Ushio博士带来了超过25年的领导在风险资本,制药,早期生命科学公司大楼。最近,作为首席执行官,她建立和构建cardiovascular-focused生物技术公司塔拉生物系统公司成功收购去年Valo健康。洋地黄企业创始人兼执行合伙人杰夫•史密斯说:“我们很高兴欢迎米洋地黄企业随着我们继续发展我们的全球团队创业,扩大,和治理专业知识在公司大楼。米带来了丰富的领导经验和科学组织,作为一个管理合伙人,她会在这两个公司洋地黄投资策略和投资组合管理。”2022年10月,洋地黄企业关闭了第四基金总额为3亿美元的承诺。新的资金将投资于领先的企业家和研究人员开发突破性的科学和技术可能改变患者的生活。Ushio博士评论道,“我狂喜的加入公司,与公认的投资领导人在生命科学、医疗技术和动物健康创新。我期待我公司建设和投资经验应用到的努力扩展洋地黄投资和组合投资,因为他们提前从初创到成长的公司。”Earlier in her career, Dr. Ushio served as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she invested in, and advised, life science companies helping them translate transformational science into commercially successful companies. Additionally, she held management roles at Merck & Company, where she developed vaccines and biologics products, and at Columbia University, where she oversaw the intellectual property of several scientific and engineering portfolios. Dr. Ushio holds a Ph.D. in Biochemical Engineering from University College London and a B.S. in Chemical Engineering from Johns Hopkins University. About Digitalis Ventures Digitalis Ventures backs founders solving critical problems in health. The firm invests in early-stage companies across the healthcare ecosystem with the goal of supporting them through multiple rounds of financing. Digitalis is based in New York City, with investors in Boston, Los Angeles, San Francisco, Gainesville, and Zurich. Contacts